It is noted that in the case of patients with recurrent cancer, the sample size and difference between AFP and the Doylestown algorithm was large enough to provide >85% power and highlight the benefit in the use of the algorithm as opposed to AFP in this setting. The gene discussed is AFP; the disease is cancer.